Downregulation of ALKBH3 resulted in human non-small-cell lung cancer regression [26], whereas downregulation of ALKBH2 increased the sensitivity of cancer cells to cisplatin, an alkylating-like anticancer drug [27]. The gene discussed is ALKBH2; the disease is cancer.